English
  • Notice: Undefined variable: sectorLink in Drupal\five_paisa\Controller\StockDetailController->getSectorLink() (line 450 of modules/custom/five_paisa/src/Controller/StockDetailController.php).
  • Warning: Illegal string offset 'stockName' in Drupal\five_paisa\Controller\StockDetailController->getData() (line 348 of modules/custom/five_paisa/src/Controller/StockDetailController.php).
  • Notice: Uninitialized string offset: 0 in Drupal\five_paisa\Controller\StockDetailController->getData() (line 348 of modules/custom/five_paisa/src/Controller/StockDetailController.php).
  • Warning: Illegal string offset 'NSEcode' in Drupal\five_paisa\Controller\StockDetailController->getData() (line 349 of modules/custom/five_paisa/src/Controller/StockDetailController.php).
  • Notice: Uninitialized string offset: 0 in Drupal\five_paisa\Controller\StockDetailController->getData() (line 349 of modules/custom/five_paisa/src/Controller/StockDetailController.php).
  • Notice: Undefined index: current_date in Drupal\futures_option\Controller\FuturesController->getOptionData() (line 398 of modules/custom/futures_option/src/Controller/FuturesController.php).
  • Warning: array_column() expects parameter 1 to be array, string given in Drupal\five_paisa\MFHoldingService->MFShareholdingTable() (line 33 of modules/custom/five_paisa/src/MFHoldingService.php).
  • Warning: array_multisort(): Argument #1 is expected to be an array or a sort flag in Drupal\five_paisa\MFHoldingService->MFShareholdingTable() (line 34 of modules/custom/five_paisa/src/MFHoldingService.php).
  • Warning: array_slice() expects parameter 1 to be array, string given in Drupal\five_paisa\MFHoldingService->MFShareholdingTable() (line 36 of modules/custom/five_paisa/src/MFHoldingService.php).
  • Warning: Invalid argument supplied for foreach() in Drupal\five_paisa\MFHoldingService->MFShareholdingTable() (line 52 of modules/custom/five_paisa/src/MFHoldingService.php).
  • Notice: Undefined index: open_price in Drupal\five_paisa\StockService::openPrevData() (line 3918 of modules/custom/five_paisa/src/StockService.php).
  • Notice: Undefined index: prev_close in Drupal\five_paisa\StockService::openPrevData() (line 3919 of modules/custom/five_paisa/src/StockService.php).
  • Notice: Undefined index: vol in Drupal\five_paisa\StockService::openPrevData() (line 3923 of modules/custom/five_paisa/src/StockService.php).
  • Notice: Undefined index: fiftytwo_low in Drupal\five_paisa\StockService::fiftyLowHighData() (line 3901 of modules/custom/five_paisa/src/StockService.php).
  • Notice: Undefined index: fiftytwo_high in Drupal\five_paisa\StockService::fiftyLowHighData() (line 3902 of modules/custom/five_paisa/src/StockService.php).
  • Notice: Undefined index: day_low in Drupal\five_paisa\StockService::dayLowData() (line 3884 of modules/custom/five_paisa/src/StockService.php).
  • Notice: Undefined index: day_high in Drupal\five_paisa\StockService::dayLowData() (line 3885 of modules/custom/five_paisa/src/StockService.php).
  1. Home
  2. Stocks
  3. Concord Share Price
  • Chart
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Concord Drugs

    Small Cap
    ₹38.89
    +0.89 (2.34%)
    01 July, 2024 06:55 BSE: 538965 NSE: CONCORDISIN: INE858L01010

    Start SIP in Concord Drugs

    Start SIP

    Concord Drugs Performance

    Day Range

    • Low 0
    • High 0
    ₹ 38

    52 Week Range

    • Low 0
    • High 0
    ₹ 38
    • Open Price0
    • Previous Close0
    • Volume

    Concord Drugs Share Price

    • Over 1 Month +5.28%
    • Over 3 Month +10.58%
    • Over 6 Month -34.88%
    • Over 1 Year +44.73%

    Concord Drugs Key Statistics

    Concord Drugs Financials
    IndicatorMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 14137912
    Operating Expenses Qtr Cr 14126711
    Operating Profit Qtr Cr 01211
    Depreciation Qtr Cr 00000
    Interest Qtr Cr 00000
    Tax Qtr Cr 00000
    Net Profit Qtr Cr 00100
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 4351
    Operating Expenses Annual Cr 4047
    Operating Profit Annual in Cr 44
    Depreciation Cr 22
    Interest Annual Cr 22
    Tax Annual Cr 00
    Net Profit Annual Cr 01
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 22
    Cash from Investing Activity Annual Cr -1-2
    Cash from Financing Annual Activity Cr -10
    Net Cash Flow Annual Cr 0
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 3432
    Fixed Assets Annual Cr 1314
    Total Non Current Assets Annual Cr 1515
    Total Current Assets Annual Cr 4141
    Total Assets Annual Cr 5657
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 3434
    ROE Annual % 13
    ROCE Annual % 68
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 98
    IndicatorMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 161389
    Operating Expenses Qtr Cr 151268
    Operating Profit Qtr Cr 0121
    Depreciation Qtr Cr 0000
    Interest Qtr Cr 1000
    Tax Qtr Cr 0000
    Net Profit Qtr Cr 0010
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 45
    Operating Expenses Annual Cr 41
    Operating Profit Annual in Cr 4
    Depreciation Cr 2
    Interest Annual Cr 2
    Tax Annual Cr 0
    Net Profit Annual Cr 0
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 1
    Cash from Investing Activity Annual Cr -1
    Cash from Financing Annual Activity Cr 0
    Net Cash Flow Annual Cr
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 34
    Fixed Assets Annual Cr 13
    Total Non Current Assets Annual Cr 14
    Total Current Assets Annual Cr 45
    Total Assets Annual Cr 59
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 34
    ROE Annual % 1
    ROCE Annual % 7
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 9
    Invest in Concord Drugs

    Concord Drugs Technicals

    EMA & SMA

    Current Price
    ₹38.89
    +0.89 (2.34%)
    • Bullish Moving Average
    • ___
    • 0
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹38.88
    • 50 Day
    • ₹38.52
    • 100 Day
    • ₹38.56
    • 200 Day
    • ₹37.73
    • 20 Day
    • ₹38.88
    • 50 Day
    • ₹38.00
    • 100 Day
    • ₹38.66
    • 200 Day
    • ₹38.63

    Concord Drugs Resistance and Support

    PIVOT
    ₹38.6
    Resistance
    First Resistance 39.69
    Second Resistance 40.49
    Third Resistance 41.58
    RSI 50.46
    MFI 61.19
    MACD Single Line 0.35
    MACD 0.24
    Support
    First Support 37.80
    Second Support 36.71
    Third Supoort 35.91

    Concord Drugs Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 5,653 513,405 90.82
    Week 69,444 3,160,387 45.51
    1 Month 36,902 1,772,772 48.04
    6 Month 24,123 1,599,089 66.29

    Concord Drugs Result Highlights

    Concord Drugs Synopsis

    NSE-Medical-Biomed/Biotech

    Concord Biotech Ltd. is involved in the business activities of Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 853.17 Cr. and Equity Capital is Rs. 10.46 Cr. for the Year ended 31/03/2023. Concord Biotech Ltd. is a Public Limited Listed company incorporated on 23/11/1984 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is U24230GJ1984PLC007440 and registration number is 007440.
    Market Cap 16,206
    Sales 1,017
    Shares in Float 5.86
    No of funds 91
    Yield
    Book Value 10.62
    U/D Vol ratio 0.5
    LTDebt / Equity
    Alpha 0.19
    Beta 0.63

    Concord Drugs Shareholding Pattern

    Owner NameMar-24Dec-23Sep-23
    Promoters 44.08%44.08%44.08%
    Mutual Funds 5.15%5.65%5.58%
    Insurance Companies 2.88%2.47%2.26%
    Foreign Portfolio Investors 6.49%7%7.3%
    Individual Investors 7.08%6.76%6.78%
    Others 34.32%34.04%34%

    Concord Drugs Management

    Name Designation
    Mr. Sudhir Vaid Chairman & Managing Director
    Mr. Ankur Vaid Joint Managing Director & CEO
    Mr. Ravi Kapoor Non Executive Director
    Mr. Rajiv Ambrish Agarwal Non Executive Director
    Mrs. Bharti Khanna Independent Director
    Mr. Amitabh Thakore Independent Director
    Mr. Arvind Agarwal Independent Director
    Mr. Jayaram Easwaran Independent Director
    Dr. Mandayam Chakravarthy Sriraman Independent Director

    Concord Drugs Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Concord Drugs Corporate Action

    Date Purpose Remarks
    2024-05-30 Audited Results (Revised)
    2024-02-13 Quarterly Results
    2023-11-14 Quarterly Results
    2023-08-14 Quarterly Results
    2023-05-30 Audited Results

    Concord Drugs MF Shareholding

    Name Amount(cr)

    Concord Drugs FAQs

    What is Share Price of Concord Drugs ?

    Concord Drugs share price is ₹38 As on 01 July, 2024 | 06:41

    What is the Market Cap of Concord Drugs ?

    The Market Cap of Concord Drugs is ₹36.2 Cr As on 01 July, 2024 | 06:41

    What is the P/E ratio of Concord Drugs ?

    The P/E ratio of Concord Drugs is 86.4 As on 01 July, 2024 | 06:41

    What is the PB ratio of Concord Drugs ?

    The PB ratio of Concord Drugs is 1.1 As on 01 July, 2024 | 06:41

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.